Which GLP-1 Providers Actually Charge You Less for Taking Less

A smaller GLP-1 dose only lowers the bill when the provider's pricing structure makes it cheaper. Flat subscriptions can charge the same amount regardless of dose, while a headline price may reflect only the lowest strength or a long prepayment term. Compare what the quoted price actually buys before choosing a plan.

The right question is narrower and rarely asked: when you take less drug, does the bill get smaller?

We priced every provider on our review index by hand against the company's own pages, funnels and, where the funnel renders nothing, its JavaScript bundles. 548 providers. Here is what the pricing structures actually look like, and it is not what the category's marketing implies.

The five ways a GLP-1 price can relate to a dose

There are only five, and the difference between them is worth more to a low-dose buyer than any headline number.

One price at every dose. A common published structure, often advertised as a feature. "Same price at every dose — no surprise increases" is genuinely reassuring if you expect to titrate upward and would rather not watch the bill climb behind you. It also means that if you deliberately stay at a quarter of the range, you are buying a quarter of the drug for the whole price. On a general weight-loss ranking this is a pro. Here it is a cost, and we score it as one. The clearest case in our ranking does not even conceal the mechanism: one provider's intake asks which weekly strength you want, in five steps from a quarter of a milligram up to two and a half, and its checkout carries no dose dimension for that answer to change — the smallest strength on the form and the largest are billed the identical figure.

One consequence of these structures is worth pricing out separately, because it decides which of them is actually cheaper for a given reader: at the median, the providers that quote off the lowest dose are the cheaper entry point, while the flat-price providers are the more predictable one. The first of those figures is a floor and the second is the whole price, so the two orderings can both be true of the same reader at different doses. The numbers are in the tirzepatide cost breakdown.

The figure is quoted off the lowest dose. More drug costs more. This is treated as a warning elsewhere — the price you are quoted is not the price you will pay once you titrate — and it is the single best structure for someone whose plan is to stay small. Fifty-two of our 548 providers do it.

A microdose is sold as its own product, with its own price. The catalog has a low-dose SKU with a separate page and a separate figure. This is the structure that sounds decisive and is not, for reasons we will come to.

Standard-dose pricing only. No low-dose product exists. Starting small means asking for less inside a standard plan, at the standard plan's price.

No dose behind the figure at all. The provider publishes a price and never says what quantity of drug it buys. Two hundred and ninety-one of the 548 are in this state, so these records cannot establish how dose changes the bill.

The trap: a named microdose tells you nothing about the price

This is the finding that surprised us, and it is the reason this page exists rather than a simple list.

A provider that builds a separate microdose product — its own page, its own checkout, its own intake — has visibly done the work. A separate product does not establish a lower price. The comparison depends on what the provider charges for each option.

On one hundred and twenty of the providers we priced, choosing to take less costs the same or more than taking a full dose. Some of those are flat-priced plans where that follows automatically. But several are companies with a genuine, purpose-built microdose SKU that they price at, or above, their own full-dose plan:

• •One provider publishes the exact dose ceiling and the full week-by-week titration behind its microdose price — genuinely the best disclosure in our ranking — and charges within a couple of dollars of its unrestricted plan for roughly a fifth of the maximum dose. Because the first-month credit that applies to its standard plans explicitly excludes the microdose, the low-dose product costs more across a year.
• •Another prices its microdose ten dollars a month above its own standard-dose injection, and sixty dollars above it over three months.
• •A third runs a microdose ladder that is byte-identical to its full-dose ladder, rung for rung, on both molecules.
• •A fourth sells its microdose at five dollars a month more than its standard plan — invisible on the site, because both products are advertised at their twelve-month prepay rungs, where the ordering between them reverses.
• •A fifth builds dedicated micro-dose landing pages for each molecule and charges the identical monthly figure as the full-dose pages.

The lesson is blunt: the existence of a named low-dose product is a catalog fact, not a price. Read the ladder, not the label.

The structures that genuinely bill you for what you take

Two shapes actually solve the problem, and both are rare.

The first is a published dose ladder. One provider prints eleven dose rungs across its two molecules with a dollar figure against each, the lowest at 0.2 mg per week — so a deliberate microdoser is billed at the bottom of the ladder rather than subsidising someone at the top of it. Note that even here the marketing fights the data: two of that provider's own product pages advertise an entry price that appears at no rung of the ladder.

The second is being sold the vial rather than the month. One provider prices per vial and states the dose each vial covers, so the same vial is a ten-week supply at the lowest dose and a five-week supply at twice it. The cost per milligram holds; the cost per month falls as the dose falls. That is the only arrangement in our ranking where the arithmetic works in a microdoser's favor automatically, and it is rare here because providers sell a plan rather than the vial.

How much the flat structure actually costs

The gap is not rhetorical. It is arithmetic, and it needs exactly two numbers you can get in a minute: what you inject, and the top of the range the provider says its one price covers.

On a plan charging one figure across 0.25–2.5 mg of semaglutide, a reader holding at 0.25 mg receives a tenth of the drug the plan is priced around, and pays all of it. That is ten times the cost per milligram someone at the top of the range pays, on the identical bill. Run your own figures through the flat-pricing calculator, which reports the share of your bill that buys drug never dispensed to you, and the annual figure that share represents.

One honest caveat travels with that number and we build it into the tool. Part of every bill is a consultation, a pharmacy fee and a cold-chain shipment, and none of those get cheaper because your vial holds less. The calculator lets you set that share aside so the premium is computed on the drug-linked part only. Left at zero, the figure it reports is the upper bound, and it says so.

There is a second cost stacked underneath, and it also only exists at the low end: a vial is a quantity of drug with a discard date, and at a small enough dose that date arrives with most of the vial still in it. What you throw away before the label says to stop is drug you have already paid for, and no provider's pricing page mentions it.

Before any of that: is the number even a month?

Six pricing constructs turned up over and over while we priced this site, and any one of them makes a comparison meaningless before the dose question is even reached.

1. 1.A prepay rung advertised as a monthly rate. The cheapest advertised figure is very often the six- or twelve-month rate payable in one charge. On one provider we priced, the advertised microdose figure is a twelve-month commitment and the real month-to-month rate is more than twice it. On another, the advertised entry price applies to a 48-week plan. The most extreme case attaches no period to anything: one provider runs nine different "starting" figures across its own pages simultaneously, with no term or billing cadence on a single one of them, and its two cheapest appear only beside a discount its own affiliate page calls money off a three-month package.
2. 2.An introductory rate presented as the price. A figure that covers the first charge and then rises is not a plan price.
3. 3.A membership billed beside the medication. Where a plan splits the two, neither number on its own is the bill, and the two are often about the same size.
4. 4.A four-week cycle called a month. Twenty-eight days is not a month: that plan bills 13.04 times a year, roughly 8.6% more than the same headline implies. A twelve-week block recurs 4.35 times a year, not four.
5. 5.One-time fees. Enrollment, intake and lab charges never appear in a monthly figure and always appear on the statement.
6. 6.A price purchasable at no tier. We found several — a microdose page headlining a figure that matches no buyable plan, a provider advertising two entry prices that appear at no rung of its own checkout, and one whose homepage, hero and plan table each quote a different number while the checkout charges none of them.

The true annual cost calculator turns those six into one form, so you can normalize any plan — including one we do not cover — before comparing it to anything.

What none of this settles

Whether a low dose is the right dose is a clinical question and this page is not about it. Everything above is about money.

It is worth being clear about the direction the clinical evidence runs, though, because the pricing conversation is easier to have honestly next to it. GLP-1 drugs follow a dose-response curve, and the curve for weight is not flat: in the pivotal oral-agent obesity trial, placebo-adjusted weight loss rose with each dose step ¹, and in the phase 3 early-diabetes trial the lowest dose captured most of the glycemic effect while delivering well under half the weight effect of the top dose ². Paying less to get proportionally less is not, on its own, a bargain — and paying the same to get less is the situation this whole page exists to help you notice.

What a lower dose does for tolerability, for lean mass, or for anything else is covered in low dose vs full dose and in what the evidence actually shows. Neither of those questions is answered by a price list, and neither should be settled by one.

The three questions to ask any provider

Before you pay anyone, in our ranking or off it:

1. 1.What dose does this price buy? If the answer is not a number in milligrams or a plainly stated range, you cannot compare this plan with any other.
2. 2.Does the price change when the dose does? "Same price at every dose" is a real answer and it means you subsidise a full dose. "It rises with the dose" is also a real answer and it is the better one for you.
3. 3.Is this figure a month? Not a prepay rung, not an introductory charge, not a four-week cycle, not a membership with the drug billed separately.

Every provider we track has those three answers written into its row, with the dose condition attached to the price everywhere the price is printed. That is the whole reason the review index groups providers by what their price says about the dose rather than sorting them cheapest-first.